The results of a phase-II study of erlotinib in patients with advanced biliary tract cancer (iCCA, eCCA, and gallbladder cancer) suggested a potential benefit in survival [105], which prompted the use of this drug in combination with other targeted agents to enhance efficacy, such as bevacizumab, a VEGF inhibitor [107], which did not improve the benefits of erlotinib administered alone. Here, VEGFA is linked to gallbladder cancer.